This study demonstrated that uptake of radiolabeled acetate is able to predict outcome of FASN-targeted therapy and that FASN inhibition not only suppressed cell proliferation but also prevented pseudopodia formation and suppressed cell adhesion, migration, and invasion, with human prostate cancer cell lines. The gene discussed is FASN; the disease is prostate carcinoma.